Report: Weak U.S. Jobs Data and Inflation Make Fed Rate Cut Next Week a...
NEW DELHI-- Softer labor market numbers combined with August’s inflation data have all but guaranteed a Federal Reserve rate cut at next week’s policy...
Infosys Gets SEC Nod for Rs 18,000 Crore Share Buyback
NEW DELHI-- Infosys has secured exemptive relief from the U.S. Securities and Exchange Commission (SEC) for its Rs 18,000 crore share buyback, marking the...
Heart of Entrepreneurship at TiECON East: Former HBS Dean Nitin Nohria in Conversation with...
BOSTON— TiE Boston is honored to announce that Nitin Nohria, former Dean of Harvard Business School and current Partner and Chairman at Thrive Capital,...
Oracle’s Larry Ellison Tops Global Rich List, Overtakes Elon Musk
NEW DELHI-- Oracle co-founder and Chief Technology Officer Larry Ellison has become the world’s richest person, surpassing Tesla CEO Elon Musk, after a historic...
Indian Markets Extend Rally for Fourth Straight Session
MUMBAI-- Indian equity benchmarks extended their winning streak to a fourth consecutive session on Thursday, closing with modest gains after a choppy start.
The Sensex...
Indian Markets Close Higher on Optimism Over U.S.–India Trade Talks
MUMBAI-- Indian equities ended higher on Wednesday, extending their positive run as investor sentiment strengthened on hopes of progress in U.S.–India trade negotiations and...
Sensex, Nifty Close Higher as Infosys Sparks IT-Led Rally
MUMBAI-- Indian equity benchmarks ended Tuesday on a strong note, lifted by a surge in technology stocks after Infosys announced its board will consider...
Gold Soars ₹1,700, Silver Hits Record as Tariff Jitters and Fed Hopes Drive Rally
NEW DELHI-- Gold and silver prices surged to fresh all-time highs on Monday, lifted by geopolitical uncertainty, U.S. tariff concerns, and rising bets on...
Sensex Inches Higher, Nifty Closes Just Below 24,800 After Volatile Session
MUMBAI-- Indian equities closed marginally higher on Monday as early momentum driven by GST reforms, easing India-U.S. trade tensions, and optimism in the auto...
Enveda Raises $150 Million, Hits Unicorn Status, Begins Lead Trial, Adds Pfizer’s Dolsten to...
BOULDER, Colo.– Enveda, a clinical-stage biotechnology company developing small-molecule drugs derived from nature’s chemistry, announced the close of a $150 million oversubscribed Series D...